Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

Roche shares positive 48-week results for investigational BTK inhibitor in relapsing MS

Approximately 2.9 million people worldwide are affected by the neurological disease

- PMLiVE

PM Society’s sixth Careers Event on 26 February 2025

The event is focused on bringing industry experts from pharmaceutical companies and agencies together to advise on career opportunities

- PMLiVE

Novavax’s JN.1-adapted COVID-19 vaccine granted FDA emergency use authorisation

JN.1 only accounts for 0.2% of cases across the country but is the ‘parent strain’ of currently circulating variants

Bayer symbol

Bayer presents positive results for Kerendia in late-stage heart failure study

Approximately 55% of the 6.7 million heart failure patients in the US have an LVEF of at least 40%

- PMLiVE

Arrowhead’s RNAi therapeutic plozasiran shows promise in familial chylomicronaemia syndrome

There are currently no therapies in the US specifically approved to treat the rare genetic disorder

- PMLiVE

Hear From Her: Extraordinary Women Who Are Redefining Healthcare Leadership

That’s a wrap for Season 2 of Medscape Education’s Award-Winning Podcast Series, Hear From Her: Women in Healthcare Leadership! (Not to worry, Season 3 is just around the corner.)  And...

Medscape Education

- PMLiVE

Leading the way on the path to patient centricity

Find out how Mednet is leading the way to a truly patient-centric future for Pharma

Mednet

- PMLiVE

Bringing Clinicians Together for Oncology Education at ESMO 2024

ESMO 2024 comes with the debut of 2 new, exciting symposia hosted by the MedscapeLIVE! team. The symposia build on nearly 30 years of Medscape’s experience and excellence in both...

Medscape Education

- PMLiVE

Merck and Astellas/Pfizer’s bladder cancer combination granted EC approval

Bladder cancer is the fifth most commonly diagnosed cancer in Europe, with more than 165,000 annual cases

- PMLiVE

Sanofi’s investigational BTK inhibitor tolebrutinib shows promise in phase 3 MS study

The neurological disorder affects approximately 2.9 million people worldwide

- PMLiVE

Alnylam shares positive phase 3 results for vutrisiran in ATTR with cardiomyopathy

The company said it will be proceeding with regulatory filings for the therapy later this year

Clipboard inside Cuttsy+Cuttsy branded shapes

Closing the loop: Why clinical trial results matter to participants

Discover why sharing clinical trial results with participants is crucial for respect, informed health decisions, and fostering strong researcher-participant partnerships.

Cuttsy + Cuttsy

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links